We have located links that may give you full text access.
Prospective Determination of the Incidence and Risk Factors of New-Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort.
Arthritis Care & Research 2018 October 16
OBJECTIVE: Identification of the incidence of Juvenile Idiopathic Arthritis (JIA)-associated uveitis and its risk factors is essential to optimize early detection. Data from the Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh-Out) inception cohort were used to estimate the annual incidence of new-onset uveitis following JIA diagnosis and identify associated risk factors.
METHODS: Data were reported every 6 months for 2 years, then yearly to 5 years. Incidence was determined by Kaplan-Meier estimators with time of JIA diagnosis as the reference point. Univariate log-rank analysis identified risk factors and Cox regression determined independent predictors.
RESULTS: In total, 1183 patients enrolled within 6 months of JIA diagnosis met inclusion criteria, median age (IQR) at diagnosis of 9.0 (3.8-12.9) years, median follow-up of 35.2 (22.7-48.3) months. Of these, 87 patients developed uveitis after enrollment. The incidence of new-onset uveitis was 2.8% per year (95% CI 2.0-3.5) in the first 5 years. The annual incidence decreased during follow-up but remained at 2.1% (95% CI 0, 4.5) in the 5th year although confidence intervals overlapped. Uveitis was associated with young age (< 7 years) at JIA diagnosis (HR=8.29, p<0.001), positive ANA (HR=3.20, p<0.001), oligoarthritis (HR=2.45, p=0.002), polyarthritis RF-negative (HR=1.65, p=0.002), female sex (HR=1.80, p=0.02). In multivariable analysis, only young age at JIA diagnosis and ANA positivity were independent predictors of uveitis.
CONCLUSION: Vigilant uveitis screening should continue for at least 5 years after JIA diagnosis and priority for screening placed on young age (< 7 years) at JIA diagnosis and a positive ANA. This article is protected by copyright. All rights reserved.
METHODS: Data were reported every 6 months for 2 years, then yearly to 5 years. Incidence was determined by Kaplan-Meier estimators with time of JIA diagnosis as the reference point. Univariate log-rank analysis identified risk factors and Cox regression determined independent predictors.
RESULTS: In total, 1183 patients enrolled within 6 months of JIA diagnosis met inclusion criteria, median age (IQR) at diagnosis of 9.0 (3.8-12.9) years, median follow-up of 35.2 (22.7-48.3) months. Of these, 87 patients developed uveitis after enrollment. The incidence of new-onset uveitis was 2.8% per year (95% CI 2.0-3.5) in the first 5 years. The annual incidence decreased during follow-up but remained at 2.1% (95% CI 0, 4.5) in the 5th year although confidence intervals overlapped. Uveitis was associated with young age (< 7 years) at JIA diagnosis (HR=8.29, p<0.001), positive ANA (HR=3.20, p<0.001), oligoarthritis (HR=2.45, p=0.002), polyarthritis RF-negative (HR=1.65, p=0.002), female sex (HR=1.80, p=0.02). In multivariable analysis, only young age at JIA diagnosis and ANA positivity were independent predictors of uveitis.
CONCLUSION: Vigilant uveitis screening should continue for at least 5 years after JIA diagnosis and priority for screening placed on young age (< 7 years) at JIA diagnosis and a positive ANA. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app